New Drug/Vaccine RNA-Peptide Named Melody Against SARS-CoV-2: Adapting Antiviral Pathways in Cell Culture WM-266 as Temporal Memory of “In Vitro Cell”

Abstract

The new coronavirus formed a clade within the subgenus Orthocoronavirinae, sarbecovirus subfamily. The first time these cases were published, and they were classified as “pneumonia of unknown etiology.” The Chinese Center for Disease Control and Prevention (CDC) and local CDCs organized an intensive outbreak investigation program. The etiology of this illness is now attributed to a novel virus belonging to the coronavirus (CoV) family, COVID-19. This disease has inflicted catastrophic damages in public health, economic and social stability-putting life globally on hold in 2020 and presumably a year more. The authorized vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) more often are Pfizer-BioNTech, Moderna, Johnson & Johnson and AstraZeneca in order to face the global pandemic COVID-19. Our aim was focused on toxicological evaluation of a new drug/vaccine model against SARS-CoV-2 with therapeutic and prophylactic actions, also useful in postCOVID-19 infection rehabilitation. Our candidate of drug/vaccine RNA-peptide named Melody was tested in cell culture WM-266 as temporal memory of “In vitro cell”. We carry out our studies of this RNA target Human Malignant Melanoma cell lines, (WM-266) monitoring dead cell number. The lethal concentration (LC) at 50% and 100% (CL50 and CL100) were calculated and reported the toxicological and efficacity findings in each study.